États-Unis · Agences & temps réel · GlobeNewswire

Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+…

Publié par GlobeNewswire · États-Unis il y a 18 h

Lire l'article complet sur GlobeNewswire Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (news.google.com)

À lire aussi

LUNGevity Foundation Launches Every Breath Forward℠ to Advance Progress and Improve Lives Nationwide

Associated Press (Business)

After years under fire, a rare quiet settles over Ukrainian city as truce holds

97% of businesses have lost revenue because payment integrations were slow or complex, Payroc research finds

Dow Jones Newswires

Takeaways from the Inaugural Dow Jones Energy Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows